NiPPeR Trial: Lower Toddler BMI, but Not Less Body Fat

A lower BMI at age 2 does not automatically mean a child carries less body fat. In the NiPPeR randomized trial, a maternal supplement begun before conception reduced the proportion of children with rapid early weight gain and was associated with lower weight and BMI at 2 years. But a later body-composition analysis found no statistically significant difference in percentage fat mass at 6 weeks, 6 months, 1 year, or 2 years.

That distinction changes the interpretation. The intervention appears to have altered the pace of growth, not selectively reduced fat tissue. It is an interesting result for early-life metabolic health, but it does not show that myo-inositol makes toddlers leaner.

The question behind the lower BMI result

NiPPeR tested a combined supplement taken from preconception through pregnancy: myo-inositol, two probiotic strains, and additional micronutrients. The comparator was a baseline micronutrient control. Earlier reports from the trial found that children in the intervention group had lower weight and BMI at age 2, and fewer met the study definition of rapid weight gain during infancy.

In the 2024 NiPPeR offspring analysis, rapid weight gain meant an increase of more than 0.67 standard deviations in weight-for-age z score between birth and age 1. The trial also reported findings through age 2, where an increase greater than 1.34 standard deviations defined rapid gain. Rapid infant weight gain is an established marker of higher later obesity and cardiometabolic risk, so this result has clinical relevance even though it is not itself a diagnosis or a measure of future disease.

Still, scales cannot distinguish fat, muscle, organs, bone, and body water. A child can weigh less because of less fat, less fat-free mass, less water, or some mixture of all three. The body-composition substudy asked the more precise question.

What the body-composition substudy found

The 2025 body-composition analysis measured children at 6 weeks, 6 months, 1 year, and 2 years. Researchers used multifrequency bioelectrical impedance spectroscopy (BIS), which estimates body composition from how the body conducts a small electrical current. Its primary endpoint was percentage fat mass: the share of total body weight made up of fat.

Percentage fat mass did not differ significantly between intervention and control children at any measured age. The central result was null. At each cross-sectional visit, the supplement group did not have a lower proportion of body fat.

At age 2, children in the control group had higher absolute fat-free mass, while percentage fat mass remained the same between groups. Fat-free mass includes water, muscle, bone, and other nonfat tissue. The most coherent reading of that pattern is that control children were larger overall, with both fat and fat-free compartments increasing in roughly similar proportions. That is an inference from the observed pattern, not proof of the biological process that produced it.

The results therefore do not support a direct anti-adiposity claim. They fit better with slower overall weight accrual in fewer children, without a detected shift in the lean-to-fat ratio at a given age.

A useful measurement, with an important limitation

The investigators did more than feed impedance values into a generic toddler calculator. They developed cohort-specific fat-free-mass prediction equations using air-displacement plethysmography measurements from the same children. At 6 weeks and 6 months, the resulting biases were below 100 grams, or less than 2% of mean fat-free mass.

That validation improves confidence in the early assessments. It does not fully solve the problem at ages 1 and 2. The researchers extrapolated the 6-month equations to those later visits, an age mismatch they acknowledged. They also compared three different equation sets—based on cohort air-displacement plethysmography, cohort DXA, and published two-year-old DXA equations—and found imperfect agreement when classifying individual children into body-composition tertiles.

So the appropriate conclusion is narrower than "there was definitely no fat-mass effect." The study detected no statistically significant difference in percentage fat mass with its available method. BIS is less accurate than DXA or air-displacement plethysmography, especially in toddlers, and equation choice affected individual-level classification. A small or moderate true difference at the older visits could have escaped detection.

The proposed glucose mechanism did not pan out

Myo-inositol was expected to improve maternal glycemia and lipid metabolism during pregnancy, potentially changing fetal metabolic programming. NiPPeR did not confirm that pathway. The trial's primary maternal glycemia endpoint at 28 weeks showed no significant between-group difference, according to the peripartum outcomes report.

That finding does not erase the child weight-trajectory result. It does mean the trial did not establish improved maternal glycemic control as its explanation. The supplement also contained probiotics and multiple micronutrients, so the study cannot identify myo-inositol, either probiotic strain, or any one vitamin as the active ingredient. A multi-ingredient trial can test the package; it cannot tell you which passenger drove the car.

Outside NiPPeR, the evidence offers biological plausibility without settling the question. A 2021 Cochrane review reported reduced gestational-diabetes incidence with probiotics, and a 2023 meta-analysis found improved fasting glucose and HOMA-IR in women with gestational diabetes who received probiotics or synbiotics. Those findings involve different populations and interventions. They cannot establish that NiPPeR's probiotic components caused the offspring result, particularly when NiPPeR's own primary glycemia endpoint was null.

What else changed during pregnancy and breastfeeding

The intervention did produce confirmed upstream nutritional changes. A prespecified secondary analysis found substantially improved maternal B-vitamin and vitamin D status from preconception through pregnancy in the NiPPeR maternal micronutrient analysis. Supplemented mothers also had higher vitamin D concentrations in human milk in a 2024 milk study.

These results show that the supplement changed maternal and milk nutrient exposure. They do not prove that those changes caused slower infant weight gain. Another NiPPeR analysis found altered milk macronutrient composition among mothers with overweight or obesity and gestational diabetes, a subgroup with higher metabolic risk. Yet milk composition does not have a simple one-way relationship with infant fatness. A 2024 study of gestational diabetes, human milk metabolites, and infant adiposity found context-dependent, non-linear associations. A compositional change in milk may matter, but its downstream effect depends on the wider metabolic and feeding context.

How much should prospective parents infer?

NiPPeR provides randomized evidence that this combined preconception-and-pregnancy regimen changed offspring weight trajectories through age 2. The finding matters because rapid early weight gain is a useful risk marker for later obesity and cardiometabolic disease. It does not demonstrate lower toddler body-fat percentage, permanent protection from obesity, or a myo-inositol-specific benefit.

Adherence in the trial was 96.6% across a regimen that began before conception and continued through pregnancy. That level of adherence may be difficult to reproduce in routine care. The multinational design also included populations with known ethnic differences in body composition; adjustment for ethnicity did not improve the study models, but subgroup effects could still be missed.

The evidence supports a change in early growth velocity, not a proven fat-reducing effect.

For people considering preconception supplements, standard prenatal care and correction of documented nutrient deficiencies remain the practical foundation. NiPPeR makes the combined intervention worth further study, especially with direct body-composition methods that remain valid into toddlerhood and trials designed to separate the ingredients. For now, its most defensible result is specific: fewer children followed a rapid weight-gain trajectory, while percentage fat mass showed no detected difference through age 2.